Table 5.

Overview of characteristics of individual patients with MEN1 with thymic carcinoids (n = 9)

Patient	Sex	Smoking status	Vital status	Total follow-up (months)	MEN1 genetic testing	MEN1-related diseases	Thymic carcinoid diagnosis	Diagnosis age of thymic carcinoid (years)	Surgery for thymic carcinoid	Adjuvant chemotherapy	Adjuvant radiotherapy	Metastasis from thymic carcinoid	Overall survivalb (years)
I	Male	No	Dead	27	Not done	PHPT: + PNET: +	Incidental	32	Thymectomy	5-FU STZ Doxorubicin Leucovorin	XRT	Lymph nodes: metachronous	22
II	Female	No	Dead	99	R98X (non-sense-deleterious, exon 2)	PHPT: + PNET: + Pituitary: +	Unknown	44	Thymectomy	5-FU STZ Doxorubicin	XRT	Lung: metachronous	19
III	Male	No	Dead	1	275_286delGCTTCACCGCCC (deletion-deleterious, exon 2)	PHPT: + PNET: + Pituitary: +	Incidental	40	Thymectomy	5-FU Leucovorin	XRT	Bones: metachronous	17
IV	Male	No	Dead	38	Not done	PHPT: + PNET: + Pituitary: +	Unknown	46	Thymectomy	None	XRT	Lung: metachronous	5
V	Female	Unknown	Dead	16	Not done	PHPT: + PNET: +	Incidental	41	Not operated	Cisplatin Etoposide Carboplatin	XRT	Bones and lymph nodes: synchronous	6
VI	Female	Noa	Dead	85	Not done	PHPT: + Pituitary: +	Symptomatic	48	Thymectomy	None	None	Bones: metachronous	8
VII	Male	Chewing tobacco use	Dead	1	W341X (non-sense-deleterious, exon 7)	PHPT: + Pituitary: +	Symptomatic	45	Thymectomy	Etoposide Carboplatin Denosumab	XRT	Lung and bones: metachronous	9
VIII	Male	No	Dead	55	Duplication of exons 9, 10 + (insertion-deleterious, exons 9 and 10)	None	Incidental	23	Thymectomy	Etoposide Cisplatin Bevacizumab AKT inhibitor (MK-2206)	IMRT	Lung, bone: synchronous Brain: metachronous	7
IX	Male	Yes	Alive	20	c.1350+(1_11)del11 (splice-deleterious, exon 9)	PHPT: + Pituitary: +	Incidental	45	Debulking thymectomy	Carboplatin Etoposide	XRT	Lung: metachronous	–

XRT X-ray radiation therapy, IMRT intensity-modulated radiotherapy, 5-FU 5-fluorouracil, STZ streptozocin

^aPatient smoked very rarely in puberty and never smoked as an adult

^bFrom time of thymic carcinoid diagnosis